Spelling suggestions: "subject:"african trypanosoma"" "subject:"frican trypanosoma""
31 |
Examination and management of human African Trypanosomiasis propagation using geospatial techniquesAkiode, Olukemi Adejoke January 2014 (has links)
Human African Trypanosomiasis (HAT) is a vector-borne disease transmitted by the bite of the tsetse fly that results in high human morbidity and mortality. The propagation of the disease has been linked to environmental factors, and understanding the vector’s habitat is vital to its control. There is no HAT vaccine, but biological control of the vector has been successful in reducing HAT incidence. However, in recent years the disease has re-emerged and spread. Due to insufficient knowledge of HAT endemic foci, the disease management remains challenging. To achieve effective deployment of control strategies, accurate knowledge of the spatial distribution of the HAT vector is vital. The current study is based in Nigeria, and looks at part of Delta State, and a part of Jigawa State, in which HAT has been identified. The work utilizes remote sensing satellite imaging and fuzzy logic to develop a HAT vector habitat classification scheme, to explore the dynamics of HAT propagation. The goal was to develop a surveillance methodology to identify factors that influence HAT epidemiology. Land cover and ancillary data were integrated to classify HAT vector habitat using geospatial-fuzzy multicriteria analysis. The work highlights the significance of geospatial techniques where epidemiological data are limited, for improving understanding of HAT. This study helped distinguish HAT vector habitat into different zones (breed, feed and rest), which allowed the direction and magnitude of HAT, a n d factors influencing propagation to be determined. This helped identify ‘HAT priority intervention areas’. The study findings suggested propagation of HAT resulted from suitability of water bodies, shrub and less-dense forest for the HAT vector, and continued exposure of human populations to these land cover classes. Overlapping of HAT vector habitat zones within built-up areas was also a cause. The study also found that HAT propagation was multidirectional, and that this may have been influenced by landscape characteristics. This novel approach can also be used in other part of Nigeria as well as adapted to investigate other diseases. In conclusion, the HAT vector habitat classification scheme is a transparent tool for policy makers for identifying vulnerable and at risk areas.
|
32 |
Synthesis and structure-activity relationship studies of 1,4-naphthoquinone derivatives as potential anti-trypanosomal agentsChakaingesu, Chikomborero January 2014 (has links)
Human African Trypanosomiasis (HAT) is an infectious, vector-borne protozoal disease which is amongst the so-called neglected diseases. In 2000, at a summit of the United Nations, eight Millennium Development Goals (MDGs) were set, to be achieved by 2015. MDG 6 states “to combat HIV/AIDS, malaria & other diseases”. With just under 2 years to go before the end of 2015, HAT is still thriving in developing countries. The drugs currently used for the treatment of HAT are in short supply, have severe side effects and those used to treat late stages of the disease are very difficult to administer. The aforementioned challenges call for research into this neglected disease in order to develop new, safe and easy-to-use medicines. Naphthoquinones are a class of compounds shown to possess anti-parasitic activity, amongst a variety of other biological activities, and therefore this pharmacophore was selected for this study. The purpose of this study was to synthesise derivatives of 2,3-dichloro-1,4- naphthoquinone to be tested for anti-trypanosomal activity and thereafter conduct structureactivity relationship studies. A series of reactions were carried out using thiophenol, phenol and aniline nucleophiles to synthesise thioether (-S-), ether (-O-) and amino (-NH-) derivatives of 2,3-dichloro-1,4-naphthoquinone with various halogen or methyl substituents. Purification of the products was carried out by recrystallisation. Nuclear magnetic resonance (NMR), infra-red (IR) and high pressure liquid chromatography coupled to an electro-spray ionisation mass spectrometer (HPLC-ESI-MS) were the analytical methods used for structural confirmation of the products. There were eighteen 1,4-naphthoquinone derivatives that were successfully synthesised using ethanolic solutions. Unfortunately, attempts to synthesise 1,4-naphthoquinones in reactions involving 2-(trifluoro-methyl)aniline and 2-isopropyl-5-methylphenol were unsuccessful, presumably due to steric hindrance by the bulky ortho-substituents. Although the aims of the synthetic procedures were to obtain both mono- and disubstituted products by nucleophilic displacement of the chlorine atom(s) of 2,3-dichloro-1,4- naphthoquinone, only monosubstituted products were obtained from substitution with aniline and phenol nucleophiles. Thiol nucleophiles, however, selectively yielded disubstituted products only. Synthesised naphthoquinone derivatives were tested against Trypanosoma brucei and calculation of the EC₅₀ values from the obtained dose-response curves was carried out using the four parametric equation. All the 1,4-naphthoquinones showed a degree of potency, except compounds 1b, 3c and 3e, which had little or lack of potency. Structure-activity relationship studies (SARs and QSARs) were carried out to determine which structural features or functional group substituents of the naphthoquinone derivatives contribute or take away from the desired anti-trypanosomal activity. It was found that compounds with the best in vitro anti-trypanosomal potencies in the series of analogous 1,4-naphthoquinone derivatives had EC₅₀ values in the range 2.137 to 2.884 μM. The most potent compound in the series was 2-chloro-3-(4-(trifluoromethyl)phenylamino)-1,4- naphthoquinone 1e; but it was 142-fold less potent than the reference standard of melarsoprol.
|
33 |
Développement de formulations colloïdales antiparasitaires pour traiter la trypanosomiase africaine / Colloidal drug delivery system in the treatment of african trypanosomiasisKroubi, Maya 21 December 2010 (has links)
Cette thèse porte sur le développement d’une formulation colloïdale de diminazène (DMZ) à l’aide de nanoparticules polysaccharidiques cationiques (NP+) pour le traitement de la Trypanosomiase Africaine (TA).Nous avons étudié dans un premier temps le procédé de chargement des NP+ en DMZ base. Nous avons constaté que l’ajout de phospholipides dans la matrice des NP+ est nécessaire à l’association de DMZ. La quantité de phospholipide est d’ailleurs le facteur limitant de l’indice de saturation des NP+ en DMZ. Afin de ne pas dégrader le principe actif, lors de son chargement, le procédé choisi est le « post-loading » qui correspond à un mode opératoire en conditions douces : ajout d’une solution de DMZ dans une suspension de NP+ à cœur huileux. Nos résultats montrent que cette formulation reste stable durant 6 mois à 4°C ne libérant pas de DMZ et le protégeant de l’oxydation. Dans un second temps, nous avons évalué l’efficacité thérapeutique du DMZ formulé. Les tests in vitro sur Trypanosoma brucei brucei montrent une amélioration de l’activité trypanocide du DMZ. Les tests réalisés sur un modèle aigu de TA, ont mis en évidence que la dose efficace est équivalente au DMZ libre (3 mg/kg). / This thesis focuses on the development of a colloidal formulation of diminazene (DMZ) using cationic polysaccharide nanoparticles (NP+) for the treatment of African Trypanosomiasis. We first studied the process of DMZ loading in NP+. The addition of phospholipids in the matrix of the NP+ appeared to be necessary for the DMZ association. So, the amount of phospholipids is the limiting factor of the saturation index of NP+ with DMZ. To avoid the drug degradation during its formulation, we choose the \\\"post-loading\\\" technique which corresponds to a procedure with mild conditions: adding a DMZ solution in a suspension of NP+ containing an oily core. DMZ loaded into 70DGNP+ was found to be protected against oxidation and was stable for at least 6 months at 4°C. In a second step, we evaluated the therapeutic efficacy of formulated DMZ. In vitro tests on Trypanosoma brucei brucei showed an improvement of the DMZ trypanocidal activity. Tests on an acute model of Trypanosomiasis showed that the effective dose is equivalent to the free DMZ (3 mg / kg).
|
34 |
Fluorescence-based reporter substrate for monitoring RNA editing in Trypanosomatid pathogensMoshiri, Houta. January 2008 (has links)
No description available.
|
35 |
Regioisomers of the Dinitroaniline Scaffold: Exploring Tubulin Assembly Inhibition through Novel Antikinetoplastid AgentsLatibeaudiere, Kirk D. 10 September 2008 (has links)
No description available.
|
36 |
Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis and CancerAbacha, Yabalu Z., Forkuo, A.D., Gbedema, S.Y., Mittal, N., Ottilie, S., Rocamora, F., Winzeler, E.A., van Schalkwyk, D.A., Kelly, J.M., Taylor, M.C., Reader, J., Birkholtz, L-M., Lisgarten, D.R., Cockcroft, J.K., Lisgarten, J.N., Palmer, R.A., Talbert, R.C., Shnyder, Steven, Wright, Colin W. 26 April 2022 (has links)
Yes / The prospect of eradicating malaria continues to be challenging in the face of increasing
parasite resistance to antimalarial drugs so that novel antimalarials active against asexual,
sexual, and liver-stage malaria parasites are urgently needed. In addition, new antimalarials
need to be affordable and available to those most in need and, bearing in mind climate
change, should ideally be sustainable. The West African climbing shrub Cryptolepis
sanguinolenta is used traditionally for the treatment of malaria; its principal alkaloid,
cryptolepine (1), has been shown to have antimalarial properties, and the synthetic
analogue 2,7-dibromocryptolepine (2) is of interest as a lead toward new antimalarial
agents. Cryptolepine (1) was isolated using a two-step Soxhlet extraction of C.
sanguinolenta roots, followed by crystallization (yield 0.8% calculated as a base with
respect to the dried roots). Semi-synthetic 7-bromo- (3), 7, 9-dibromo- (4), 7-iodo- (5), and
7, 9-dibromocryptolepine (6) were obtained in excellent yields by reaction of 1 with
N-bromo- or N-iodosuccinimide in trifluoroacetic acid as a solvent. All compounds
were active against Plasmodia in vitro, but 6 showed the most selective profile with
respect to Hep G2 cells: P. falciparum (chloroquine-resistant strain K1), IC50 = 0.25 µM, SI
= 113; late stage, gametocytes, IC50 = 2.2 µM, SI = 13; liver stage, P. berghei sporozoites
IC50 = 6.13 µM, SI = 4.6. Compounds 3–6 were also active against the emerging zoonotic species P. knowlesi with 5 being the most potent (IC50 = 0.11 µM). In addition, 3–6 potently
inhibited T. brucei in vitro at nM concentrations and good selectivity with 6 again being the
most selective (IC50 = 59 nM, SI = 478). These compounds were also cytotoxic to wild-type
ovarian cancer cells as well as adriamycin-resistant and, except for 5, cisplatin-resistant
ovarian cancer cells. In an acute oral toxicity test in mice, 3–6 did not exhibit toxic effects at
doses of up to 100 mg/kg/dose × 3 consecutive days. This study demonstrates that C.
sanguinolenta may be utilized as a sustainable source of novel compounds that may lead
to the development of novel agents for the treatment of malaria, African trypanosomiasis,
and cancer.
|
37 |
Ethyl Pyruvate and HIV-1 Protease Inhibitors in Drug Discovery of Human African TrypanosomiasisMengistu, Netsanet 28 September 2015 (has links) (PDF)
Referat:
Background: Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious disease of humans caused by an extracellular protozoan parasite. The disease, if left untreated, results in 100% mortality. However, the available drugs are full of severe drawbacks and fail to escape the fast development of trypanosoma resistance. Due to the probable similarities in cell metabolism among tumor and trypanosoma cells, some of the current registered drugs against HAT were derived from cancer chemotherapeutic research. Here too, for the first time, we have demonstrated that the simple ester, ethyl pyruvate, comprises such properties. On the other hand initial studies have confirmed the efficacy of protease inhibitors in treatment of Trypanosoma cruzi, Plasmodium falciparum and Leishmania major. However, studies on efficacy and specific proteases inhibition using HIV-1 protease inhibitors on T. brucei cells remain untouched.
Methodology/Principal findings: The current study covers efficacy and corresponding target evaluation of ethyl pyruvate and HIV-1 protease inhibitors (ritonavir and saquinavir) on T. brucei cell lines using a combination of biochemical techniques including cell proliferation assays, enzyme kinetics, zymography, phase contrast microscopic video imaging and ex vivo drug toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by net ATP depletion through inhibition of pyruvate kinase (Ki=3.0±0.29 mM). The potential of this compound as an anti-trypanosomal drug is also strengthened by its fast acting property, killing cells within three hours post exposure. This was demonstrated using video imaging of live cells as well as concentration and time dependency experiments. Most importantly, this drug produced minimal side effects in human erythrocytes and is known to easily cross the blood-brain-barrier (BBB) which makes it a promising candidate for effective treatment of the two clinical stages of sleeping sickness. Trypanosome drug resistance tests indicate irreversible killing of cells and a low chance of drug resistance development under applied experimental conditions. In addition to ethyl pyruvate our experimental study on HIV-1 protease inhibitors showed that both ritonavir (RTV) (IC50=12.23 µM) and saquinavir (SQV) (IC50=11.49 µM) effectively inhibited T. brucei cells proliferation. The major proteases identified in these cells were the cysteine- (~29kDa Mr) and metallo- (~66kDa Mr) proteases. Their proteolytic activity was, however, not hampered by either of these two protease inhibitors.
Conclusion/Significance: Our results present ethyl pyruvate as a safe and fast acting drug. Hence, because of its predefined property to easily cross the BBB, it can probably be a new candidate agent to treat the heamolymphatic as well as neurological stages of sleeping sickness. Similarly, HIV-1 protease inhibitors, SQV and RTV, exhibited their antitrypanosomal potential but require further anlysis to identify their specific targets.
|
38 |
Ethyl Pyruvate and HIV-1 Protease Inhibitors in Drug Discovery of Human African TrypanosomiasisMengistu, Netsanet 21 September 2015 (has links)
Referat:
Background: Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious disease of humans caused by an extracellular protozoan parasite. The disease, if left untreated, results in 100% mortality. However, the available drugs are full of severe drawbacks and fail to escape the fast development of trypanosoma resistance. Due to the probable similarities in cell metabolism among tumor and trypanosoma cells, some of the current registered drugs against HAT were derived from cancer chemotherapeutic research. Here too, for the first time, we have demonstrated that the simple ester, ethyl pyruvate, comprises such properties. On the other hand initial studies have confirmed the efficacy of protease inhibitors in treatment of Trypanosoma cruzi, Plasmodium falciparum and Leishmania major. However, studies on efficacy and specific proteases inhibition using HIV-1 protease inhibitors on T. brucei cells remain untouched.
Methodology/Principal findings: The current study covers efficacy and corresponding target evaluation of ethyl pyruvate and HIV-1 protease inhibitors (ritonavir and saquinavir) on T. brucei cell lines using a combination of biochemical techniques including cell proliferation assays, enzyme kinetics, zymography, phase contrast microscopic video imaging and ex vivo drug toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by net ATP depletion through inhibition of pyruvate kinase (Ki=3.0±0.29 mM). The potential of this compound as an anti-trypanosomal drug is also strengthened by its fast acting property, killing cells within three hours post exposure. This was demonstrated using video imaging of live cells as well as concentration and time dependency experiments. Most importantly, this drug produced minimal side effects in human erythrocytes and is known to easily cross the blood-brain-barrier (BBB) which makes it a promising candidate for effective treatment of the two clinical stages of sleeping sickness. Trypanosome drug resistance tests indicate irreversible killing of cells and a low chance of drug resistance development under applied experimental conditions. In addition to ethyl pyruvate our experimental study on HIV-1 protease inhibitors showed that both ritonavir (RTV) (IC50=12.23 µM) and saquinavir (SQV) (IC50=11.49 µM) effectively inhibited T. brucei cells proliferation. The major proteases identified in these cells were the cysteine- (~29kDa Mr) and metallo- (~66kDa Mr) proteases. Their proteolytic activity was, however, not hampered by either of these two protease inhibitors.
Conclusion/Significance: Our results present ethyl pyruvate as a safe and fast acting drug. Hence, because of its predefined property to easily cross the BBB, it can probably be a new candidate agent to treat the heamolymphatic as well as neurological stages of sleeping sickness. Similarly, HIV-1 protease inhibitors, SQV and RTV, exhibited their antitrypanosomal potential but require further anlysis to identify their specific targets.:Bibliographic description ii
Acronyms iii
1. Introduction 1
1.1. Disease background 1
1.2. Epidemiological distribution and disease transmission dynamics 1
1.3. Biology and life cycle of the trypanosomatidea 3
1.4. Public health significance 4
1.5. Clinical stages and disease progression 5
1.6. Current challenges of disease control 6
1.7. Current drugs and their clinical applications 9
1.8. Targets for drug discovery 12
1.8.1. Energy metabolism 12
1.8.2. Proteolysis 17
1.9. Ethyl pyruvate 18
1.10. HIV-1 Protease Inhibitors 21
2. Aim of the study 22
3. Materials and Methods 24
4. Results 31
5. Discussion 45
6. Conclusion 53
7. Supporting information 54
8. Summary 56
9. References 62
Erklärung über die eigenständige Abfassung der Arbeit 77
Curriculum vitae 78
Publications and Presentations 81
Acknowledgement 83
|
39 |
Synthèse et étude de l'activité anti-kinétoplastidés de nouvelles 8-nitroquinoléin-2(1H))-ones bioactivées par les nitroréductases de type 1 / Synthesis and study of the antikinetoplastid activity of new 8-nitroquinolin-2(1H)-ones bioactivated by type 1 nitroreductasesPedron, Julien 05 October 2018 (has links)
Les kinétoplastidés sont des protozoaires flagellés responsables de maladies tropicales négligées mortelles telles que la leishmaniose viscérale (L. donovani et L. infantum) ou la trypanosomiase humaine africaine (T. brucei), pour lesquelles les traitements disponibles sont très limités. Depuis quelques années, on observe un regain d'intérêt pour le développement de nitrohétérocycles aromatiques anti-infectieux tels que le delamanide et le féxinidazole. De récentes études indiquent que l'activité anti-kinétoplastidés de ces dérivés repose sur leur bioactivation sélective par des nitroréductases parasitaires, conduisant à la formation de métabolites réduits électrophiles, fortement cytotoxiques. Suite à des études préliminaires réalisées dans notre équipe en série 8-nitroquinoléin-2(1H)-one, ces travaux de thèse portent sur la synthèse et l'étude in vitro de l'activité antiparasitaire de 80 dérivés notamment fonctionnalisés en positions 3 et 6 du pharmacophore par divers motifs, notamment via la mise au point de réactions d'halogénation sélective et de couplages pallado-catalysés. Ainsi, 5 nouvelles molécules hits (4 anti-kinétoplastidés et 1 sélective de T. brucei) ont été identifiées (0,01 µM ≤ CI50 ≤ 7 µM et 13 < IS < 1500), trois d'entre-elles étant des substrats sélectifs des nitroréductases parasitaires de type I. Afin de préciser les relations structure-activité, une étude des potentiels de réduction a également été menée. Des études physico-chimiques (solubilité, test de perméabilité PAMPA) et pharmacocinétiques in vitro (stabilité microsomale et fixation à l'albumine humaine) sont venues compléter ce travail. Enfin, des évaluations de la mutagénicité et de la génotoxicité de ces hits sur des cellules procaryotes et humaines ont été conduites, dans le but de statuer sur leur potentiel pharmaceutique antiparasitaire humain et vétérinaire. / Kinetoplastids are flagellated protozoan parasites responsible for lethal neglected tropical diseases, such as visceral leishmaniasis (L. donovani and L. infantum) or sleeping sickness (T. brucei brucei), for which very few drugs are available. Nowadays, nitroheterocyclic compounds present a renewed interest as anti-infective agents, as illustrated by the development of fexinidazole and delamanid. Some recent studies demonstrated that the antikinetoplastid activity of these derivatives involves their selective bioactivation by parasitic nitroreductases, leading to the formation of electrophilic reduced metabolites, highly cytotoxic. Based on preliminary studies conducted in our team in 8-nitroquinolin-2(1H)-one series, this PhD work is about the synthesis and in vitro antiparasitic study of 80 derivatives mainly functionalized at positions 3 and 6 of the pharmacophore by various substituents, especially via the optimization of selective halogenation and pallado-catalyzed cross coupling reactions. Thereby, 5 new hit compounds (4 antikinetoplastid and 1 selective of T. brucei) were identified (0.01 µM ≤ IC50 ≤ 7 µM and 13 < SI < 1500), three of them being selective substrates of type I parasitic nitroreductases. In order to refine the structure-activity relationship studies, an analysis of reduction potentials was also conducted. In vitro physicochemical (solubility, PAMPA permeability assay) and pharmacokinetic (microsomal stability and human albumin binding) experiments completed this work. Finally, the mutagenicity and genotoxicity evaluations of these new hit compounds toward prokaryotic and human cells were realized, in order to assess their human and veterinary antiparasitic pharmaceutical potential.
|
40 |
Ethyl pyruvate emerges as a safe and fast acting agent against Trypanosoma brucei by targeting pyruvate kinase activityWorku, Netsanet, Stich, August, Daugschies, Arwid, Wenzel, Iris, Kurz, Randy, Thieme, Rene, Kurz, Susanne, Birkenmeier, Gerd 18 September 2015 (has links) (PDF)
Background: Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious disease in humans caused by an extracellular protozoan parasite. The disease, if left untreated, results in 100% mortality. Currently available drugs are full of severe drawbacks
and fail to escape the fast development of trypanosoma resistance. Due to similarities in cell metabolism between cancerous tumors and trypanosoma cells, some of the current registered drugs against HAT have also been tested in cancer chemotherapy. Here we demonstrate
for the first time that the simple ester, ethyl pyruvate, comprises such properties.
Results: The current study covers the efficacy and corresponding target evaluation of ethyl pyruvate on T. brucei cell lines using a combination of biochemical techniques including cell proliferation assays, enzyme kinetics, phasecontrast microscopic video imaging and ex vivo toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by net ATP depletion through inhibition of pyruvate kinase (Ki = 3.0±0.29 mM). The potential of ethyl pyruvate as a trypanocidal compound is also strengthened by its fast acting property, killing cells within three hours post exposure. This has been demonstrated using video
imaging of live cells as well as concentration and time dependency experiments. Most importantly, ethyl pyruvate produces minimal side effects in human red cells and is known to easily cross the blood-brain-barrier. This makes it a promising candidate for effective treatment of the two clinical stages of sleeping sickness. Trypanosome drug-resistance tests indicate irreversible cell death and a low incidence of resistance development under experimental conditions.
Conclusion: Our results present ethyl pyruvate as a safe and fast acting trypanocidal compound and show that it inhibits the enzyme pyruvate kinase. Competitive inhibition of this enzyme was found to cause ATP depletion and cell death. Due to its ability to easily cross the bloodbrain-
barrier, ethyl pyruvate could be considered as new candidate agent to treat the hemolymphatic as well as neurological stages of sleeping sickness.
|
Page generated in 0.308 seconds